Structure-based virtual screening, in vitro and in vivo analyses identified kaempferol 3-gentiobioside as an FXR partial agonist protecting against cholestatic liver disease
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Structure-based virtual screening, in vitro and in vivo analyses identified kaempferol 3-gentiobioside as an FXR partial agonist protecting against cholestatic liver disease. // Bioorganic & Medicinal Chemistry. – URL: https://www.sciencedirect.com/science/article/pii/S0968089626002981?dgcid=rss_sd_all
Structure-based virtual screening, in vitro and in vivo analyses identified kaempferol 3-gentiobioside as an FXR partial agonist protecting against cholestatic liver disease. Bioorganic & Medicinal Chemistry. https://www.sciencedirect.com/science/article/pii/S0968089626002981?dgcid=rss_sd_all
“Structure-based virtual screening, in vitro and in vivo analyses identified kaempferol 3-gentiobioside as an FXR partial agonist protecting against cholestatic liver disease.” Bioorganic & Medicinal Chemistry.
@article{article73147,
title = {Structure-based virtual screening, in vitro and in vivo analyses identified kaempferol 3-gentiobioside as an FXR partial agonist protecting against cholestatic liver disease},
journal = {Bioorganic \& Medicinal Chemistry},
url = {https://www.sciencedirect.com/science/article/pii/S0968089626002981?dgcid=rss_sd_all}
}